东北制药集团股份有限公司第九届董事会 独立董事 2024 年第三次专门会议审议意见 根据《深圳证券交易所股票上市规则》《上市公司独立董事规则》和《东北 制药集团股份有限公司章程》《东北制药集团股份有限公司独立董事工作细则》 等有关规定，作为东北制药集团股份有限公司（以下简称"公司"）的独立董事， 我们对第九届董事会独立董事 2024 年第三次专门会议的相关议案进行了认真审 议，现就相关议案发表审议意见如下： 一、关于新增关联方及新增 2024 年度日常关联交易预计的议案 公司及子公司与相关关联方之间的关联交易均为生产经营活动所必需，属于 正常业务往来。依据市场价格协商定价，遵循公平、合理的原则，根据实际情况 签订合同，不存在利用关联方关系损害上市公司利益的情形，不损害公司股东特 别是中小股东的利益。综上所述，我们一致同意将上述议案提交公司第九届董事 会第三十次会议进行审议，关联董事应回避表决。该议案尚需提交公司股东大会 审议。 二、关于控股股东及其他关联方占用公司资金、公司对外担保情况的议案 （一）关于公司 2024 年半年度控股股东及其他关联方占用资金情况 报告期内，公司与控股股东及其他关联方发生的资金往来 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-052 东北制药集团股份有限公司 关于新增关联方及新增 2024 年度日常关联交易预计的公告 公司于 2024 年 3 月 28 日召开第九届董事会第二十五次会议和第九届监事会 第二十次会议，审议通过了《关于调整 2024 年度日常关联交易预计的议案》。 为适应市场需求，更好开展各项业务，根据公司日常经营的实际需要，公司需对 2024 年度日常关联交易预计金额进行调整。经业务部门重新测算，公司及子公 司 2024 年度同关联方发生各类日常关联交易预计总额调整为 24,410 万元。具体 内容详见公司于巨潮资讯网披露的《东北制药集团股份有限公司关于调整 2024 年度日常关联交易预计的公告》（公告编号：2024-018）。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （二）审议程序 公司于 2024 年 8 月 27 日召开第九届董事会第三十次会议，以同意 5 票，反 对 0 票，弃权 0 票，回避 6 票，审议通过了《关于新增关联方及新增 2024 年度 日常关联交易预计的议案》，关联董事郭建 ...

Group 1: Company Strategy and Acquisition - The company is cautiously considering strategic transformation into the field of cell therapy, emphasizing the importance of thorough research and assessment before making significant changes [2] - Northeast Pharmaceutical plans to acquire 70% of the equity of Dingcheng Peptide Source, aligning with the vision of its actual controller in the cell therapy sector [3] Group 2: Research and Development Team - Dingcheng Peptide Source was established in 2014 and has a solid foundation in technology development, focusing on the discovery of TCR sequences since 2017 [3] - The R&D team consists of 121 members, with over 20 holding doctoral degrees and more than 50% having master's degrees [3] Group 3: Market Potential and Interest in Cell Therapy - There is a significant unmet medical need in tumor treatment, which cell therapy can address, making it an area of interest for the company [4] - The company views cell therapy as a strategic opportunity to gain a competitive advantage in the biopharmaceutical sector [4] Group 4: Product Development and Clinical Trials - Dingcheng Peptide Source is not in the first tier in terms of product approval or clinical stages, but its TCR-T product is expected to be the first in China to enter Phase I clinical trials targeting KRAS G12D [4] - The company has developed a robust TCR sequence library, which is crucial for future product development [5] Group 5: Cost Control and Efficiency - Northeast Pharmaceutical has implemented effective measures for cost control and efficiency improvement, focusing on detailed management to reduce waste and enhance productivity [5]

Group 1: Acquisition Background - Northeast Pharmaceutical Group Co., Ltd. is pursuing a transformation towards biopharmaceuticals and has been seeking suitable acquisition targets [2] - The company plans to acquire 70% of the shares of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. as conditions for the acquisition have matured [3] Group 2: Dingcheng Peptide Source's Technology and R&D Progress - Dingcheng Peptide Source, established in 2014, focuses on developing cell therapy products for solid tumors and is advancing two products into clinical trials [3] - One product targets KRAS-G12D TCR-T and has received implied approval for clinical trials from CDE, while another CAR-T product for glioblastoma received orphan drug designation from the FDA [3] - The company has developed multiple cell therapy products targeting gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer, ready for IND application [3] Group 3: Clinical and Market Strategy - The KRAS mutation is prevalent in many solid tumors, with G12D being the most common in pancreatic cancer, colorectal cancer, small cell lung cancer, and ovarian cancer [5] - The company aims to prioritize high-expression indications for clinical trials and will consider expanding based on phase I results [5] Group 4: Financial and Operational Plans - The company will support Dingcheng Peptide Source's R&D without setting specific financial limits, aligning with market development progress [6] - Post-acquisition, the R&D team will have equity incentives to ensure stability and motivation [6] - The acquisition is a strategic move reflecting the management's confidence in transitioning to biopharmaceuticals [6]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别风险提示： 证券代码：000597 证券简称：东北制药 公告编号：2024-048 东北制药集团股份有限公司 关于股价异动的公告 东北制药集团股份有限公司与张嵘先生签署《股权收购框架协议》，拟收购北京鼎 成肽源生物技术有限公司 70%的股权。本次股权收购事项尚存在不确定性。截止 2023 年 12 月 31 日，北京鼎成肽源生物技术有限公司总资产为 4,519.23 万元，净资产为 -31,156.58 万元；2023 年度，营业收入为 174.86 万元，净利润为-12,915.20 万元， 短期内为公司带来投资回报的可能性较小。敬请广大投资者注意投资风险。 一、股票交易异常波动情况 东北制药集团股份有限公司（以下简称"公司"），公司股票（证券简称： 东北制药，证券代码：000597）于 2024 年 8 月 7 日、8 月 8 日连续 2 个交易日 收盘价格涨幅偏离值累计达 21.22%，根据深圳证券交易所有关规定，属于股票 交易异常波动情况。 二、公司关注并核实情况的说明 针对公司股票异常波动，公司对有 ...

Financial Data and Key Metrics Changes - The acquisition of 70% stake in Dingcheng Taiyuan is seen as a significant step for Northeast Pharmaceutical to expand its presence in the biopharmaceutical sector, bringing mature product lines, core technologies, and advanced laboratory facilities [1][2] - The company aims to leverage this acquisition to create new profit growth points and enhance its long-term development through technological innovation [1][2] Business Line Data and Key Metrics Changes - The focus is on cell therapy, particularly in the TCRT area, which is expected to present both opportunities and challenges for the company [1][2] - The company plans to accelerate the R&D process and optimize product registration pathways, emphasizing the importance of R&D investment [1][4] Market Data and Key Metrics Changes - The vitamin C market has shown better-than-expected performance in the first half of the year, with stable prices contributing to a positive outlook for the company's future performance [8][23] - The company is taking a cautious approach to investment direction in the biopharmaceutical sector to ensure investor interests are protected [8][24] Company Strategy and Development Direction - Northeast Pharmaceutical is committed to becoming a leading drug production and export base in China, focusing on integrating raw materials and formulations [3] - The company emphasizes the importance of R&D investment, particularly in innovative drug development, and plans to maintain a stable R&D team post-acquisition [6][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the TCRT platform and the ability to optimize costs, aiming to reduce prices significantly in the future [13][24] - The company is optimistic about the future of its vitamin C segment and is actively monitoring market demand and production capacity [8][23] Other Important Information - The acquisition is expected to be completed within 120 days, with ongoing support for R&D during the integration process [5][14] - The company is exploring strategies for patent layout and registration pathways to expedite the approval process for innovative drugs [4][15] Q&A Session Summary Question: What was the main focus of the conference call? - The main focus was on the acquisition of a 70% stake in Dingcheng Taiyuan and its implications for the company's strategic development [10] Question: Why did Northeast Pharmaceutical choose to acquire Dingcheng Taiyuan? - The acquisition aims to strengthen the company's strategic deployment in the biopharmaceutical sector and quickly enter the cell therapy field [10][12] Question: What key achievements does Dingcheng Taiyuan have in the biopharmaceutical field? - Dingcheng Taiyuan has a product pipeline from early R&D to clinical phase I, along with valuable core technologies and a well-established R&D team [11] Question: What is the expected timeline for the product pipeline and clinical data release post-acquisition? - The timeline will be disclosed gradually based on the acquisition process and regulatory requirements [13] Question: How is the company planning to control costs and reduce prices for the TCRT platform? - The company aims to optimize costs significantly and has already achieved price reductions in some regions [13] Question: What is the company's strategy regarding the vitamin C market? - The company maintains a cautious optimism regarding the vitamin C market, focusing on quality and stability while monitoring market dynamics [23][24]

Group 1: Company Overview and Strategic Moves - Northeast Pharmaceutical has a 78-year history, primarily focusing on APIs and chemical generics, and is expanding into biopharmaceuticals [3] - The acquisition of 70% of Dingsheng Peptide Source marks a significant strategic move into the cell therapy field, aiming for rapid business growth through resource integration and technology accumulation [3][4] - The company established a biopharmaceutical R&D center in Shanghai in 2022, focusing on antibody drugs and ADCs [3] Group 2: Acquisition Benefits and Technical Advancements - The acquisition provides access to a promising product pipeline developed since 2014, with potential clinical applications [3] - Northeast Pharmaceutical gains specific core technologies in cell therapy, which would take 3-5 years to develop from scratch [3] - The acquisition includes a mature R&D team and well-equipped laboratories capable of supporting early-phase clinical trials [3] Group 3: Future Plans and Market Positioning - The company plans to optimize costs for CAR-T therapies through supply chain management and collaboration with leading hospitals [4] - There is a commitment to maintaining R&D progress during the acquisition process, with expectations for early clinical trial data to be available soon [4] - The company is exploring overseas market opportunities for product licensing to enhance financial and brand value [5] Group 4: Financial Outlook and Market Performance - The average market price for Vitamin C has increased by nearly $1, indicating a positive trend compared to the previous year [6] - The company anticipates improved profitability in the Vitamin C segment due to better market conditions and cost management [6] - The management expresses confidence in the transition to biopharmaceuticals, expecting fruitful outcomes from the acquisition and ongoing R&D efforts [7]

来参加东北制药收购顶层派员的这样的一个事件的交流的电话会那我们今天非常荣幸的请到东北制药的财务总监宋佳伦宋总首席科学家冯晓冯博士以及董秘严小佳严总和郑代严总来一起跟大家交流这次收购的一些情况我是申万红园的医药分析师张静涵今天跟我一起在线主持的还有我们组负责原料药板块的 于玉军和负责创新药板块的杨佳佳好那接下来我们就先有请公司领导宋总来跟大家简单介绍一下鼎城太原以及我们这次东北之药这个收购鼎城太原70%股权的一个大概的情况有请宋总好感谢这个神万宏园的这个领导还有各位这个潜在的这个投资者或者是已经是成为投资者的这个各位领导简单说一下因为根据这个已经披露的信息呢 东北之钥呢是你收购这个鼎城太原生物医药公司70%的股权然后鼎城太原这个公司的基本介绍呢相信大家也都在网上啊或者什么地方也都查到了然后我们昨天披露的这些相关的信息其中呢里边涉及了一些鼎城太原的一些技术的一些资料是已经披露的包括涉及的一些靶点试验证以及目前这个研发所处在这个阶段 顶层太原这家公司呢就是一会儿这个由冯博士会这个做一下关于他技术层面以及未来的研发方向这样的一个简介以及东北制药自2022年以来这个逐渐的这个稳步的向生物药这块转型这样的一个未来的一个战 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-046 会议审议并以记名投票表决方式通过以下议案： 议案：关于签署《股权收购框架协议》的议案 东北制药集团股份有限公司 第九届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第九届董事会第二十九 次会议于 2024 年 7 月 31 日发出会议通知，于 2024 年 8 月 5 日以通讯表决的方 式召开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 特此公告。 东北制药集团股份有限公司董事会 2024 年 8 月 6 日 具体内容详见公司于同日披露于巨潮资讯网的《东北制药集团股份有限公司 关于签署股权收购框架协议的公告》（公告编号：2024-047）。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 三、备 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-047 东北制药集团股份有限公司 关于签署股权收购框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1.东北制药集团股份有限公司（以下简称"公司"）与张嵘先生签署《股权 收购框架协议》，拟收购北京鼎成肽源生物技术有限公司（以下简称"鼎成肽源"） 70%的股权。 2.本次签署的协议仅为股权收购的框架性协议，股权收购事项尚需根据评估 结果等最终确定，交易安排以交易各方最终签署的正式股权转让协议为准，本次 股权收购事项尚存在不确定性。 3.本框架协议涉及的后续事宜，公司将按照《中华人民共和国公司法》（以 下简称《公司法》）《深圳证券交易所股票上市规则》（以下简称《上市规则》） 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》（以 下简称《规范运作》）及《东北制药集团股份有限公司章程》（以下简称《公司 章程》）等相关法律法规和公司制度的规定及要求履行相应的决策和审批程序， 并及时履行相关信息披露义务。 一、交易概述 1.根据公司业务发展需要，公司于近日与张 ...